IDERA PHARMACEUTICALS, INC. IDRA Cash Flow

Idera pharmaceuticals, inc. (IDRA)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows from Operating Activities:
Net income (loss)
8,817	-23,232	-11,133	-11,176	-10,974	-12,150	-11,605	-16,031	-20,095	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-15,057	-	-12,903	-13,485	-12,823	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,365	-12,719	-12,481	-	-9,455	-8,308	-8,961	-6,090	-4,738	-3,591	-3,807	-3,798	-4,669	-3,887	-6,886	-5,160	-5,489	-6,282	-6,845
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-employee stock option expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-353	255	240	32	-5	-14	11	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
750	977	963	889	1,016	1,220	1,327	1,538	1,589	1,555	1,623	5,758	1,784	1,720	1,630	1,781	1,716	1,429	1,144	1,523	1,346	2,236	766	785	535	404	476	265	253	468	505	535	588	631	655	779	660
Warrant liability revaluation income
-1,101	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Future tranche right liability revaluation income
-20,711	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from disposition of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-	-	-	-
Issuance of common stock for services rendered
26	37	33	36	23	20	32	22	23	31	45	31	43	43	65	32	32	32	30	41	19	20	26	22	14	-	-	-	2	-	-	-	4	0	-5	0	6
Decrease in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,321	-	-	-	-
Issuance of common stock for services rendered
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	13	12	13
Accretion of discounts on short-term investments
18	-5	24	172	181	-	-	-	-	0	-2	-18	-74	-100	-106	-165	-195	-202	-198	-113	-86	-64	-53	-50	-46	-	-	-	-	-	-	-	-	-3	-13	-17	-29
Unrealized gain on available-for-sale securities
-	-	-	0	-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization expense
24	26	27	32	35	37	74	152	169	187	191	192	176	172	167	160	157	142	133	112	101	71	57	47	31	31	31	33	42	-	-	-	-	-	-	-	-
Gain on disposal of property and equipment
-	0	-1	3	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	51	67	83	-	120	125	128
Changes in operating assets and liabilities:
Prepaid expenses and other assets
-1,313	-138	1,875	-153	576	-836	-1,812	1,272	-1,341	323	-540	-26	2,205	-1,112	36	-34	46	726	764	-133	532	101	266	-324	286	477	195	26	-22	54	-101	-12	2	-216	-366	-237	179
Accounts payable, accrued expenses, and other liabilities
148	152	1,169	268	-2,694	-1,321	-3,788	1,827	2,416	2,067	386	1,404	-2,183	1,051	816	1,933	-1,812	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-141	-187	-278	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued expenses, and other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	682	-1,488	-	771	939	1,008	1,573	-285	-1,003	-211	-221	-597	-708	-889	158	-91	179	-72
Deferred revenue
-	-	-	-	-	-94	-141	-141	-190	-	-	-	-	-278	-278	-278	-277	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-10,748	-10,327	-10,841	-9,973	-13,357	-11,472	-11,792	-13,905	-14,747	-11,500	-11,884	-14,229	-17,646	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,713	-5,302	-5,780	-3,582	-4,418	-4,932	-6,260
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,855	-	-11,761	-9,860	-12,709	-9,511	-8,053	-6,155	-7,602	-4,462	-4,669	-4,307	-3,699	-	-	-	-	-	-	-	-
Cash Flows from Investing Activities:
Purchases of available-for-sale securities
5,535	55	8,961	1	35,485	-	-	-	-	-	-	-	-	0	0	0	2,946	0	6,910	52,522	3,674	21,004	0	2,003	616	-	-	-	-	-	-	-	-	0	0	0	1,025
Proceeds from maturity of available-for-sale securities
2,749	-	-	-	-	-	-	-	-	1,400	1,175	8,975	16,720	2,800	8,650	12,057	9,239	5,818	10,000	7,000	6,602	-	-	-	-	-	-	-	-	-	-	-	-	1,000	1,000	5,200	11,385
Proceeds from the sale of property and equipment
-	0	0	3	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1,974	0	0	0	999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
7	0	0	7	4	4	29	28	14	106	0	70	30	39	102	177	90	68	283	271	105	202	358	521	12	5	3	0	1	-	-	-	-	2	0	3	18
Net cash used in investing activities
-2,793	6,195	3,539	23,345	-35,481	93	164	-28	-14	1,294	1,175	8,905	16,690	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	998	1,000	5,299	10,342
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,177	-	2,807	-45,793	3,822	-19,091	-358	-524	-628	-9,336	-3	0	-1	-	-	-	-	-	-	-	-
Proceeds from common stock financings, net
1,406	1,441	0	2,272	1,585	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock warrants and options and employee stock purchases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,862	1	1	-	-	-	-	-	-	-	-
Dividends paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	558	349	160	160	160	160	103	-	-	-	-
Proceeds from employee stock purchases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	4	20	23
Proceeds from employee stock purchases
25	-	-	-	26	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	0	0	-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from employee stock purchases
-	-	-	-	-	-	46	78	81	-	69	58	57	-	-	-	-	-	0	-471	81,070	-	-65	-176	37,378	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock options and warrants
-	-	-	-	-	-	-	-	9,591	-	-	-	-	1,889	44	31	36	1,559	644	222	121	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prior year financing transaction costs paid in current year
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	-	-	-	87	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock warrants and options and employee stock purchases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,352	1,012	5,768	-	-	-	-	-	-	-	-	-	-	-	-
Dividends paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	216	119	118	345	-	-	-	-	-	-	-	-	-	-	-	-
Payments on note payable
-	-	-	-	-	0	0	131	78	76	74	72	70	68	66	64	63	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on capital leases
-	-	-	-	-	-	-	-	-	2	4	1	4	1	1	3	2	2	4	2	2	1	2	1	1	1	1	1	1	-	-	-	-	0	0	4	4
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29	-	581	-251	81,189	82	2,016	817	42,700	1,327	27,120	14,459	-247	-	-	-	-	-	-	-	-
Net cash provided by financing activities
1,431	11,540	29	2,314	1,605	37	44	520	9,591	58,894	-9	289	-17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-162	-160	-102	9,077	4	16	19
Net decrease in cash and cash equivalents
-12,110	7,408	-7,273	15,686	-47,233	-11,342	-11,584	-13,413	-5,170	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-10,718	-5,035	-973	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Increase to right-of-use asset upon adoption of ASC 842
-	-	-	-	261	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase to lease liability upon adoption of ASC 842
-	-	-	-	261	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash financing and investing activities:
Capitalized offering costs in accounts payable and accrued expenses
260	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,910	2,185	-4,707	-1,410	-8,373	-55,904	72,302	-28,520	-6,395	-5,862	34,470	-12,471	22,448	10,152	-3,947	1,744	-4,875	-5,462	-5,882	6,493	-3,414	383	4,101